Future research should focus on evaluating the efficacy and safety of HDAC inhibitors in patients with T2DM-CRC co-morbidities, as well as elucidating the specific mechanisms by which the HDAC contributes to CRC progression in the context of T2DM. The gene discussed is HDAC9; the disease is colorectal carcinoma.